Day: August 9, 2024

— Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH — Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 –– — Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer –– SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. “The second quarter of 2024 brought important progress for EFX with the initiation of the Phase 3 SYNCHRONY Outcomes...

DALLAS, Aug. 09, 2024 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled financial services holding company that provides liquidity, primary capital solutions and related trust and custody services to holders of alternative assets, announced that it will present at the Sidoti Micro-Cap Virtual Conference, which will take place virtually on August 14-15, 2024. The Company will present at 2:30 p.m. EDT on Thursday, August 15, 2024. Investors can register for the conference here and for the Beneficient presentation through this link. Additionally, investors participating in the conference can request a 1×1 meeting via their Sidoti representative or contact Beneficient investor relations via investors@beneficient.com. About Beneficent Beneficient (Nasdaq: BENF) – Ben, for short – is on...

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on the Events and Presentations page of Gyre’s website. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million MHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma CARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 study Cash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profitSOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights. “In the second...

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (NASDAQ: AMCX) today reported financial results for the second quarter ended June 30, 2024. Chief Executive Officer Kristin Dolan said: “AMC Networks continues to find opportunities in a strategic plan built around programming, partnerships and profitability. Key to our plan is the creation and curation of celebrated films and series, and making them available to audiences everywhere, including through an exciting new branded content licensing agreement with Netflix. In the first half of 2024, we’ve made significant progress against our strategic priority of generating strong free cash flow, and we’re well on our way to achieving our free cash flow guidance for the full year.” Operational Highlights:Expanded...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce that further to its press release of July 29, 2024 in connection with a non-brokered private placement (the “Offering”) to raise up to $2 million in gross proceeds, the Company has received additional interest and is increasing the Offering to up to $2.3 million (the “Upsized Offering”). The Upsized Offering will comprise of up to 5,750,000 units of the Company (each a “Unit”) at a price of $0.40 per Unit (the “Issue Price”) for gross proceeds of up to approximately $2.3 million. Each Unit will consist of one common share of the Company (each, a “Common Share”) and one-half of one common share...

ATLANTA, Aug. 09, 2024 (GLOBE NEWSWIRE) — Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended June 30, 2024. “We began the second half of 2024 executing on our Enterprise channel strategy to expand into additional verticals with the successful launch of our new platform purpose-built for Medicaid to 750,000 members on July 1,” said Brent Layton, CEO of Sharecare. “I am very enthusiastic about the opportunity to drive activation, engagement, and positive impact in these verticals at scale, leveraging our highly configurable digital capabilities, data, and services while continuing to deepen our relationships with large employers, health plans, and value-based companies, which remain important cornerstones for the company’s...

Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials Closed $140 million upsized underwritten public offering and concurrent registered direct offering Ended the second quarter with $431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) —  ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024. “The interim results...

SHANGHAI, Aug. 09, 2024 (GLOBE NEWSWIRE) — Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) dated August 7, 2024, indicating that for the last 34 consecutive business days, the closing bid price of the Company’s American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s ADSs on Nasdaq. Pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar...

Highlights Strong Operational and Financial Performance and Declares Quarterly Dividends DALLAS, Aug. 09, 2024 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) announced second quarter 2024 results and declared quarterly dividends totaling $0.17 per share. The details for today’s earnings call and webcast are listed below. Quarterly Highlights & Recent AnnouncementsProduced 25,300 Boe/d, flat to first quarter; above the midpoint of 2024 annual guidance of 25,200 boe/d Cost reductions on pace, highlighted by 11% sequential quarter decrease in Lease Operating Expenses Declared second quarter dividends of $0.17 per share, including $0.12/share fixed and $0.05/share variable Four horizontal farm-in wells from the Uinta Basin’s prolific Uteland Butte reservoir performing above pre-drill estimates Reported...